JPWO2021146218A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021146218A5 JPWO2021146218A5 JP2022542784A JP2022542784A JPWO2021146218A5 JP WO2021146218 A5 JPWO2021146218 A5 JP WO2021146218A5 JP 2022542784 A JP2022542784 A JP 2022542784A JP 2022542784 A JP2022542784 A JP 2022542784A JP WO2021146218 A5 JPWO2021146218 A5 JP WO2021146218A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cdr2
- cdr3
- cdr1
- chain variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010001517 Galectin 3 Proteins 0.000 claims 21
- 102100039558 Galectin-3 Human genes 0.000 claims 21
- 239000012634 fragment Substances 0.000 claims 21
- 230000008499 blood brain barrier function Effects 0.000 claims 12
- 210000001218 blood-brain barrier Anatomy 0.000 claims 12
- 238000000034 method Methods 0.000 claims 10
- 125000003275 alpha amino acid group Chemical group 0.000 claims 9
- 229940127121 immunoconjugate Drugs 0.000 claims 8
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 8
- 230000035699 permeability Effects 0.000 claims 7
- 102000005962 receptors Human genes 0.000 claims 7
- 108020003175 receptors Proteins 0.000 claims 7
- 206010014599 encephalitis Diseases 0.000 claims 6
- 208000024827 Alzheimer disease Diseases 0.000 claims 5
- 206010002022 amyloidosis Diseases 0.000 claims 5
- 230000002452 interceptive effect Effects 0.000 claims 5
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 claims 4
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 claims 4
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 claims 4
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 239000002955 immunomodulating agent Substances 0.000 claims 4
- 230000002584 immunomodulator Effects 0.000 claims 4
- 229940121354 immunomodulator Drugs 0.000 claims 4
- 230000003993 interaction Effects 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 230000001737 promoting effect Effects 0.000 claims 4
- 239000013589 supplement Substances 0.000 claims 4
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims 3
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims 3
- 208000003174 Brain Neoplasms Diseases 0.000 claims 3
- 208000023105 Huntington disease Diseases 0.000 claims 3
- 208000018737 Parkinson disease Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 230000009689 neuronal regeneration Effects 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 210000004881 tumor cell Anatomy 0.000 claims 3
- 208000030507 AIDS Diseases 0.000 claims 2
- 229940126638 Akt inhibitor Drugs 0.000 claims 2
- 102100034452 Alternative prion protein Human genes 0.000 claims 2
- 108091023037 Aptamer Proteins 0.000 claims 2
- 206010054793 Arterial fibrosis Diseases 0.000 claims 2
- 208000006373 Bell palsy Diseases 0.000 claims 2
- ZEOWTGPWHLSLOG-UHFFFAOYSA-N Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F Chemical compound Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F ZEOWTGPWHLSLOG-UHFFFAOYSA-N 0.000 claims 2
- 206010010904 Convulsion Diseases 0.000 claims 2
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims 2
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims 2
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims 2
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 2
- 102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 claims 2
- 101710182386 Fibroblast growth factor receptor 1 Proteins 0.000 claims 2
- 206010016654 Fibrosis Diseases 0.000 claims 2
- 208000001914 Fragile X syndrome Diseases 0.000 claims 2
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 2
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 2
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 201000009906 Meningitis Diseases 0.000 claims 2
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000029726 Neurodevelopmental disease Diseases 0.000 claims 2
- 229940123066 Polymerase inhibitor Drugs 0.000 claims 2
- 108091000054 Prion Proteins 0.000 claims 2
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims 2
- 102000008233 Toll-Like Receptor 4 Human genes 0.000 claims 2
- 108010060804 Toll-Like Receptor 4 Proteins 0.000 claims 2
- 208000000323 Tourette Syndrome Diseases 0.000 claims 2
- 208000016620 Tourette disease Diseases 0.000 claims 2
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 2
- 208000036826 VIIth nerve paralysis Diseases 0.000 claims 2
- 208000018756 Variant Creutzfeldt-Jakob disease Diseases 0.000 claims 2
- 206010047249 Venous thrombosis Diseases 0.000 claims 2
- 241000710886 West Nile virus Species 0.000 claims 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 2
- 201000007201 aphasia Diseases 0.000 claims 2
- 208000005881 bovine spongiform encephalopathy Diseases 0.000 claims 2
- 230000009787 cardiac fibrosis Effects 0.000 claims 2
- 239000002458 cell surface marker Substances 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims 2
- 231100000433 cytotoxic Toxicity 0.000 claims 2
- 230000001472 cytotoxic effect Effects 0.000 claims 2
- 230000004064 dysfunction Effects 0.000 claims 2
- 206010015037 epilepsy Diseases 0.000 claims 2
- 201000006061 fatal familial insomnia Diseases 0.000 claims 2
- 230000004761 fibrosis Effects 0.000 claims 2
- 229940051026 immunotoxin Drugs 0.000 claims 2
- 230000002637 immunotoxin Effects 0.000 claims 2
- 239000002596 immunotoxin Substances 0.000 claims 2
- 231100000608 immunotoxin Toxicity 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- 210000000274 microglia Anatomy 0.000 claims 2
- 239000003607 modifier Substances 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 229920000642 polymer Polymers 0.000 claims 2
- 239000003197 protein kinase B inhibitor Substances 0.000 claims 2
- 235000018102 proteins Nutrition 0.000 claims 2
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 2
- 201000002793 renal fibrosis Diseases 0.000 claims 2
- 208000020431 spinal cord injury Diseases 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 230000009529 traumatic brain injury Effects 0.000 claims 2
- 206010059245 Angiopathy Diseases 0.000 claims 1
- 102000014461 Ataxins Human genes 0.000 claims 1
- 108010078286 Ataxins Proteins 0.000 claims 1
- 206010003694 Atrophy Diseases 0.000 claims 1
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 1
- 208000014644 Brain disease Diseases 0.000 claims 1
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 claims 1
- 206010008025 Cerebellar ataxia Diseases 0.000 claims 1
- 208000011990 Corticobasal Degeneration Diseases 0.000 claims 1
- 206010011659 Cutaneous amyloidosis Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 206010064553 Dialysis amyloidosis Diseases 0.000 claims 1
- 208000032274 Encephalopathy Diseases 0.000 claims 1
- -1 ErbB2 Proteins 0.000 claims 1
- 208000034846 Familial Amyloid Neuropathies Diseases 0.000 claims 1
- 102000008946 Fibrinogen Human genes 0.000 claims 1
- 108010049003 Fibrinogen Proteins 0.000 claims 1
- 102100023600 Fibroblast growth factor receptor 2 Human genes 0.000 claims 1
- 101710182389 Fibroblast growth factor receptor 2 Proteins 0.000 claims 1
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 claims 1
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 claims 1
- 102100027844 Fibroblast growth factor receptor 4 Human genes 0.000 claims 1
- 208000002339 Frontotemporal Lobar Degeneration Diseases 0.000 claims 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 102100022623 Hepatocyte growth factor receptor Human genes 0.000 claims 1
- 101000917134 Homo sapiens Fibroblast growth factor receptor 4 Proteins 0.000 claims 1
- 101000972946 Homo sapiens Hepatocyte growth factor receptor Proteins 0.000 claims 1
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 claims 1
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 claims 1
- 101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 claims 1
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 claims 1
- 101000851030 Homo sapiens Vascular endothelial growth factor receptor 3 Proteins 0.000 claims 1
- 208000029400 Inclusion myopathy Diseases 0.000 claims 1
- 102000004877 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- 208000027747 Kennedy disease Diseases 0.000 claims 1
- 108010063045 Lactoferrin Proteins 0.000 claims 1
- 102100032241 Lactotransferrin Human genes 0.000 claims 1
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 206010059282 Metastases to central nervous system Diseases 0.000 claims 1
- 208000001089 Multiple system atrophy Diseases 0.000 claims 1
- 101150038994 PDGFRA gene Proteins 0.000 claims 1
- 101710176384 Peptide 1 Proteins 0.000 claims 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims 1
- 102000018967 Platelet-Derived Growth Factor beta Receptor Human genes 0.000 claims 1
- 108010051742 Platelet-Derived Growth Factor beta Receptor Proteins 0.000 claims 1
- 208000024777 Prion disease Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 208000027583 Serpinopathy Diseases 0.000 claims 1
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 claims 1
- 208000032859 Synucleinopathies Diseases 0.000 claims 1
- 208000034799 Tauopathies Diseases 0.000 claims 1
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 claims 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims 1
- 102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 claims 1
- 208000006269 X-Linked Bulbo-Spinal Atrophy Diseases 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 230000002776 aggregation Effects 0.000 claims 1
- 238000004220 aggregation Methods 0.000 claims 1
- 229960003852 atezolizumab Drugs 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 230000001746 atrial effect Effects 0.000 claims 1
- 230000037444 atrophy Effects 0.000 claims 1
- 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 claims 1
- 229950002916 avelumab Drugs 0.000 claims 1
- 230000005540 biological transmission Effects 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 210000002798 bone marrow cell Anatomy 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 229950007712 camrelizumab Drugs 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 229940121420 cemiplimab Drugs 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 210000003591 cerebellar nuclei Anatomy 0.000 claims 1
- 230000002490 cerebral effect Effects 0.000 claims 1
- 230000001268 conjugating effect Effects 0.000 claims 1
- 230000021615 conjugation Effects 0.000 claims 1
- 230000007850 degeneration Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 229950009791 durvalumab Drugs 0.000 claims 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 1
- 229940012952 fibrinogen Drugs 0.000 claims 1
- 208000010544 human prion disease Diseases 0.000 claims 1
- 201000008319 inclusion body myositis Diseases 0.000 claims 1
- 229940125396 insulin Drugs 0.000 claims 1
- 229960005386 ipilimumab Drugs 0.000 claims 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 claims 1
- 229940078795 lactoferrin Drugs 0.000 claims 1
- 235000021242 lactoferrin Nutrition 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 229960003301 nivolumab Drugs 0.000 claims 1
- 230000000242 pagocytic effect Effects 0.000 claims 1
- 229960002621 pembrolizumab Drugs 0.000 claims 1
- 208000030153 prolactin-producing pituitary gland adenoma Diseases 0.000 claims 1
- 210000003994 retinal ganglion cell Anatomy 0.000 claims 1
- 210000001625 seminal vesicle Anatomy 0.000 claims 1
- 229940121497 sintilimab Drugs 0.000 claims 1
- 229950007213 spartalizumab Drugs 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 229950007123 tislelizumab Drugs 0.000 claims 1
- 229950007217 tremelimumab Drugs 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 201000010653 vesiculitis Diseases 0.000 claims 1
- 208000027121 wild type ATTR amyloidosis Diseases 0.000 claims 1
Claims (12)
前記エピトープが、配列番号3~26に記載の任意のアミノ酸配列、またはこれらの任意の組合せを含む、the epitope comprises any amino acid sequence set forth in SEQ ID NOs: 3 to 26, or any combination thereof;
抗Gal3抗体またはその結合性断片。Anti-Gal3 antibody or binding fragment thereof.
前記VH-CDR1が、配列番号27~44、245~246、および588~615からなる群から選択されるアミノ酸配列を含み、
前記VH-CDR2が、配列番号45~60、247~248、および616~643からなる群から選択されるアミノ酸配列を含み、
前記VH-CDR3が、配列番号61~81、249~250、および644~671からなる群から選択されるアミノ酸配列を含み、
前記VL-CDR1が、配列番号82~101、251~252、および672~699からなる群から選択されるアミノ酸配列を含み、
前記VL-CDR2が、配列番号102~116、253、および700~727からなる群から選択されるアミノ酸配列を含み、ならびに
前記VL-CDR3が、配列番号117~135、254~255、および728~755からなる群から選択されるアミノ酸配列を含む、請求項1に記載の抗Gal3抗体またはその結合性断片。 (1) a heavy chain variable region comprising V H -CDR1, V H -CDR2, and V H -CDR3; and (2) a light chain variable region comprising V L -CDR1, V L -CDR2, and V L -CDR3. including ;
the V H -CDR1 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs : 27-44 , 245-246, and 588-615;
the V H -CDR2 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs : 45-60 , 247-248, and 616-643;
the V H -CDR3 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs : 61-81 , 249-250, and 644-671;
the V L -CDR1 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs : 82-101, 251-252, and 672-699;
said V L -CDR2 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 102-116 , 253, and 700-727, and
The anti-Gal3 antibody or binding fragment thereof according to claim 1 , wherein the V L -CDR3 comprises an amino acid sequence selected from the group consisting of SEQ ID NO : 1 17-135, 254-255, and 728-755.
(b)Gal3の領域内に存在するエピトープに結合し、前記エピトープが、ペプチド6(GAYPGQAPPGAYPGAPGAYP;配列番号8)を含む;
(c)Gal3の領域内に存在するエピトープに結合し、前記エピトープが、ペプチド7(AYPGAPGAYPGAPAPGVYPG;配列番号9)を含む;
(d)Gal3のN末端ドメイン、Gal3のN末端、もしくはGal3のタンデムリピートドメイン(TRD)に結合する;
(e)前記重鎖可変領域が、配列番号136~160、256~257、もしくは756~783に記載の任意の配列に対して少なくとも75%、80%、85%、90%、95%、もしくは100%の配列同一性を有するアミノ酸配列を含む;
(f)前記重鎖可変領域が、配列番号136~160、256~257、および756~783からなる群から選択される;
(g)前記軽鎖可変領域が、配列番号161~187、258~259、もしくは784~811に記載の任意の配列に対して少なくとも75%、80%、85%、90%、95%、もしくは100%の配列同一性を有するアミノ酸配列を含む;
(h)前記軽鎖可変領域が、配列番号161~187、258~259、および784~811からなる群から選択される;
(i)F846C.1B2、F846C.1F5、F846C.1H12、F846C.1H5、F846C.2H3、F846TC.14A2、F846TC.14E4、F846TC.16B5、F846TC.7F10、F847C.10B9、F847C.11B1、F847C.12F12、F847C.26F5、F847C.4B10、F849C.8D10、F849C.8H3、846.2B11、846.4D5、846.2D4、846.2F11、846T.10B1、846T.2E3、846T.4C9、846T.4E11、846T.4F5、846T.8D1、847.10C9、847.11D6、847.15D12、847.15F9、847.15H11、847.20H7、847.21B11、847.27B9、847.28D1、847.2B8、847.3B3、849.1D2、849.2D7、849.2F12、849.4B2、849.4F12、849.4F2、849.5C2、849.8D12、F847C.21H6、およびこれらの結合性断片からなる群から選択される;
(j)経腸的に、経口的に、鼻腔内に、非経口的に、頭蓋内に、皮下に、筋肉内に、皮内に、もしくは静脈内に、もしくはこれらの任意の組合せで投与される;または
(k)血液脳関門を通過することができる、請求項1に記載の抗Gal3抗体またはその結合性断片。 (a) binds to an epitope present in the region of Gal3, the epitope comprising peptide 1 (ADNFSLHDALSGSGNPNPQG; SEQ ID NO: 3);
(b) binds to an epitope present in the region of Gal3, the epitope comprising peptide 6 (GAYPGQAPPGAYPGAPGAYP; SEQ ID NO: 8);
(c) binds to an epitope present in the region of Gal3, the epitope comprising peptide 7 (AYPGAPGAYPGAPAPGVYPG; SEQ ID NO: 9);
(d) binds to the N-terminal domain of Gal3, the N-terminus of Gal3, or the tandem repeat domain (TRD) of Gal3;
(e) the heavy chain variable region is at least 75%, 80%, 85%, 90%, 95%, or Contains amino acid sequences with 100% sequence identity;
(f) said heavy chain variable region is selected from the group consisting of SEQ ID NOs: 136-160, 256-257, and 756-783;
(g) said light chain variable region is at least 75%, 80%, 85%, 90%, 95%, or Contains amino acid sequences with 100% sequence identity;
(h) said light chain variable region is selected from the group consisting of SEQ ID NOs: 161-187, 258-259, and 784-811;
(i) F846C. 1B2, F846C. 1F5, F846C. 1H12, F846C. 1H5, F846C. 2H3, F846TC. 14A2, F846TC. 14E4, F846TC. 16B5, F846TC. 7F10, F847C. 10B9, F847C. 11B1, F847C. 12F12, F847C. 26F5, F847C. 4B10, F849C. 8D10, F849C. 8H3, 846.2B11, 846.4D5, 846.2D4, 846.2F11, 846T. 10B1, 846T. 2E3, 846T. 4C9, 846T. 4E11, 846T. 4F5, 846T. 8D1, 847.10C9, 847.11D6, 847.15D12, 847.15F9, 847.15H11, 847.20H7, 847.21B11, 847.27B9, 847.28D1, 847.2B8, 847.3B3, 849.1D2, 849.2D7, 849.2F12, 849.4B2, 849.4F12, 849.4F2, 849.5C2, 849.8D12, F847C. 21H6, and binding fragments thereof;
(j) administered enterally, orally, intranasally, parenterally, intracranially, subcutaneously, intramuscularly, intradermally, or intravenously, or any combination thereof; or
(k) The anti-Gal3 antibody or binding fragment thereof according to claim 1 , which is capable of passing through the blood-brain barrier .
(b)それを必要とする対象における、炎症、脳炎、アルツハイマー病、パーキンソン病、ハンチントン病、外傷性脳傷害、脊髄傷害、多発性硬化症、筋萎縮性側索硬化症、嗅覚機能障害、失語症、ベル麻痺、伝達性海綿状脳症、クロイツフェルト-ヤコブ病、致死性家族性不眠症、癲癇、発作、神経発達症、トゥレット症候群、神経感染性障害、髄膜炎、脳炎、ウシ海綿状脳症、ウエストナイルウイルス脳炎、Neuro-AIDS、脆弱X症候群、ギラン-バレー症候群、脳への転移、脳のがん、もしくはこれらの任意の組合せの処置における使用のための;
(c)それを必要とする対象におけるアルツハイマー病の処置における使用のための、Gal3とアミロイド前駆体タンパク質(APP)もしくはアミロイドベータ(Aβ)、もしくは両方との結合を妨害する;
(d)それを必要とする対象におけるミクログリアの貪食機能の促進における使用のための;
(e)それを必要とする対象におけるミクログリアのAβ媒介性活性化の阻害における使用のための;
(f)それを必要とする対象におけるAβ原線維もしくはオリゴマー形成の阻害における使用のための;
(g)それを必要とする対象における、Gal3とToll様受容体4(TLR4)もしくは骨髄細胞上に発現されるトリガー受容体2(TREM2)、もしくは両方との相互作用の妨害における使用のための;
(h)それを必要とする対象におけるプロテオパチーの処置における使用のための;
(i)それを必要とする対象における、アルツハイマー病、脳β-アミロイド血管障害、緑内障における網膜神経節細胞変性症、パーキンソン病、レビー認知症、多系統萎縮症
、シヌクレイン病、ピック病、大脳皮質基底核変性症、タウオパチー、前頭側頭葉変性症、ハンチントン病、歯状核赤核淡蒼球ルイ体萎縮症、球脊髄性筋萎縮症、脊髄小脳運動失調症、脆弱X症候群、バラテラ-スコット症候群、フリードライヒ運動失調症、筋強直性ジストロフィー、アレキサンダー病、家族性英国型認知症、家族性デンマーク型認知症、ペリツェウス-メルツバッヘル病、セイピノパチー、AA(二次性)アミロイドーシス、II型糖尿病、フィブリノーゲンアミロイドーシス、透析アミロイドーシス、封入体筋炎/ミオパチー、家族性アミロイドニューロパチー、老年性全身性アミロイドーシス、セルピノパチー、心房性アミロイドーシス、下垂体プロラクチノーマ、インスリンアミロイドーシス、角膜ラクトフェリンアミロイドーシス、肺胞蛋白症、精嚢アミロイド、皮膚苔癬アミロイドーシス、マロリー小体、歯原性(ピンドボルグ)腫瘍アミロイド、タンパク質のミスフォールディングもしくは凝集により引き起こされる任意の疾患、もしくはこれらの任意の組合せの処置における使用のための;
(j)それを必要とする対象におけるニューロン再生の促進における使用のための;
(k)炎症、脳炎、アルツハイマー病、パーキンソン病、ハンチントン病、外傷性脳傷害、脊髄傷害、多発性硬化症、筋萎縮性側索硬化症、嗅覚機能障害、失語症、ベル麻痺、伝達性海綿状脳症、クロイツフェルト-ヤコブ病、致死性家族性不眠症、癲癇、発作、神経発達症、トゥレット症候群、神経感染性障害、髄膜炎、脳炎、ウシ海綿状脳症、ウエストナイルウイルス脳炎、Neuro-AIDS、脆弱X症候群、ギラン-バレー症候群、脳への転移、脳のがん、もしくはこれらの任意の組合せと関連付けられるニューロン変性症を有する対象におけるニューロン再生の促進における使用のための;
(l)アルツハイマー病と関連付けられるニューロン変性症を有する対象におけるニューロン再生の促進における使用のための、Gal3とアミロイド前駆体タンパク質(APP)もしくはアミロイドベータ(Aβ)、もしくは両方との結合を妨害する;
(m)線維症、肝臓線維症、非アルコール性脂肪肝疾患(NAFLD)、非アルコール性脂肪性肝炎(NASH)、腎臓線維症、心臓線維症、動脈線維症、静脈血栓症、肺線維症、免疫関連障害、敗血症、アトピー性皮膚炎、乾癬、もしくはがんの処置のための医薬もしくは組成物の製造における使用のための;
(n)PD1/PDL1遮断療法もしくはCTLA4遮断療法に対するサプリメントとして使用するための医薬もしくは組成物の製造における使用のための;
(o)ペムブロリズマブ、ニボルマブ、セミプリマブ、スパルタリズマブ、カムレリズマブ、シンチリマブ、チスレリズマブ、トリパリマブ、AMP-224、AMP-514、アテゾリズマブ、アベルマブ、デュルバルマブ、KN035、CK-301、AUNP12、CA-170、および/もしくはBMS-986189に対するサプリメントとして使用するための医薬もしくは組成物の製造における使用のための;
(p)標準治療処置に対するサプリメントとしての使用のための;
(q)イピリムマブおよび/もしくはトレメリムマブに対するサプリメントとして使用するための医薬もしくは組成物の製造における使用のための;ならびに/または
(r)それを必要とする対象における、線維症、肝臓線維症、非アルコール性脂肪肝疾患(NAFLD)、非アルコール性脂肪性肝炎(NASH)、腎臓線維症、心臓線維症、動脈線維症、静脈血栓症、もしくは肺線維症の処置における使用のための、請求項1に記載の抗Gal3抗体またはその結合性断片。 (a) for use in the treatment of neurodegenerative disorders in a subject in need thereof;
(b) inflammation, encephalitis, Alzheimer's disease, Parkinson's disease, Huntington's disease, traumatic brain injury, spinal cord injury, multiple sclerosis, amyotrophic lateral sclerosis, olfactory dysfunction, aphasia in a subject in need thereof; , Bell's palsy, transmissible spongiform encephalopathy, Creutzfeldt-Jakob disease, fatal familial insomnia, epilepsy, seizures, neurodevelopmental disorders, Tourette's syndrome, neuroinfectious disorders, meningitis, encephalitis, bovine spongiform encephalopathy, For use in the treatment of West Nile virus encephalitis, Neuro-AIDS, Fragile X syndrome, Guillain-Barre syndrome, brain metastases, brain cancer, or any combination thereof;
(c) interfering with the binding of Gal3 to amyloid precursor protein (APP) or amyloid beta (Aβ), or both, for use in the treatment of Alzheimer's disease in a subject in need thereof;
(d) for use in promoting the phagocytic function of microglia in a subject in need thereof;
(e) for use in inhibiting Aβ-mediated activation of microglia in a subject in need thereof;
(f) for use in inhibiting Aβ fibril or oligomer formation in a subject in need thereof;
(g) for use in interfering with the interaction of Gal3 with Toll-like receptor 4 (TLR4) or trigger receptor expressed on bone marrow cells 2 (TREM2), or both in a subject in need thereof; ;
(h) for use in the treatment of proteopathy in a subject in need thereof;
(i) Alzheimer's disease, cerebral β-amyloid angiopathy, retinal ganglion cell degeneration in glaucoma, Parkinson's disease, Lewy dementia, multiple system atrophy in subjects in need thereof;
, synucleinopathies, Pick's disease, corticobasal degeneration, tauopathy, frontotemporal lobar degeneration, Huntington's disease, dentate nucleus pallidum Luysian atrophy, spinobulbar muscular atrophy, spinocerebellar ataxia Fragile amyloidosis, type II diabetes, fibrinogen amyloidosis, dialysis amyloidosis, inclusion body myositis/myopathy, familial amyloid neuropathy, senile systemic amyloidosis, serpinopathy, atrial amyloidosis, pituitary prolactinoma, insulin amyloidosis, corneal lactoferrin amyloidosis, alveoli For use in the treatment of proteinosis, seminal vesicle amyloid, lichen cutaneous amyloidosis, Mallory bodies, odontogenic (pindborg) tumor amyloid, any disease caused by protein misfolding or aggregation, or any combination thereof. of;
(j) for use in promoting neuronal regeneration in a subject in need thereof;
(k) Inflammation, encephalitis, Alzheimer's disease, Parkinson's disease, Huntington's disease, traumatic brain injury, spinal cord injury, multiple sclerosis, amyotrophic lateral sclerosis, olfactory dysfunction, aphasia, Bell's palsy, transmission spongiosis Encephalopathy, Creutzfeldt-Jakob disease, fatal familial insomnia, epilepsy, seizures, neurodevelopmental disorders, Tourette syndrome, neuroinfectious disorders, meningitis, encephalitis, bovine spongiform encephalopathy, West Nile virus encephalitis, Neuro-AIDS , for use in promoting neuronal regeneration in a subject with neuronal degeneration associated with Fragile X syndrome, Guillain-Barré syndrome, metastases to the brain, cancer of the brain, or any combination thereof;
(l) interfering with the binding of Gal3 to amyloid precursor protein (APP) or amyloid beta (Aβ), or both, for use in promoting neuronal regeneration in subjects with neuronal degeneration associated with Alzheimer's disease;
(m) fibrosis, liver fibrosis, nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), renal fibrosis, cardiac fibrosis, arterial fibrosis, venous thrombosis, pulmonary fibrosis, For use in the manufacture of a medicament or composition for the treatment of immune-related disorders, sepsis, atopic dermatitis, psoriasis, or cancer;
(n) for use in the manufacture of a medicament or composition for use as a supplement to PD1/PDL1 blockade therapy or CTLA4 blockade therapy;
(o) pembrolizumab, nivolumab, cemiplimab, spartalizumab, camrelizumab, sintilimab, tislelizumab, tripalimab, AMP-224, AMP-514, atezolizumab, avelumab, durvalumab, KN035, CK-301, AUNP12, CA-170, and/or For use in the manufacture of a medicament or composition for use as a supplement to BMS-986189;
(p) For use as a supplement to standard therapeutic treatment;
(q) for use in the manufacture of a medicament or composition for use as a supplement to ipilimumab and/or tremelimumab; and/or
(r) fibrosis, liver fibrosis, nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), renal fibrosis, cardiac fibrosis, arterial fibrosis in a subject in need thereof; 2. The anti-Gal3 antibody or binding fragment thereof of claim 1 for use in the treatment of venous thrombosis or pulmonary fibrosis .
請求項1に記載の抗Gal3抗体またはその結合性断片;および
前記抗Gal3抗体またはその結合性断片にコンジュゲートされたペイロードを含み、
血液脳関門を通過することができる、
抗体コンジュゲート。 An antibody conjugate comprising:
The anti-Gal3 antibody or binding fragment thereof according to claim 1 ; and a payload conjugated to the anti-Gal3 antibody or binding fragment thereof,
able to cross the blood-brain barrier,
Antibody conjugate.
関門を通過する透過性が低い;
(b)前記抗Gal3抗体もしくはその結合性断片への前記ペイロードのコンジュゲーションが、前記血液脳関門を通過する前記ペイロードの透過性を、コンジュゲートされていない前記ペイロードと比較して、少なくとも5%、10%、20%、30%、40%、50%、60%、70%、80%、90%、100%、200%、300%、400%、もしくは500%、もしくは上述のパーセンテージの任意の2つにより定義される範囲内の任意の増加だけ増加させる;
(c)前記血液脳関門を通過する前記ペイロードの透過性が、前記血液脳関門を通過する前記抗体コンジュゲートの透過性の95%、90%、80%、70%、60%、50%、40%、30%、20%、10%、9%、8%、7%、6%、5%、4%、3%、2%、もしくは1%より低い;
(d)前記ペイロードが、細胞傷害性ペイロード、微小管妨害剤、DNA修飾剤、Akt阻害剤、ポリメラーゼ阻害剤、検出可能な部分、免疫調節剤、免疫モジュレーター、免疫毒素、核酸ポリマー、アプタマー、ペプチド、タンパク質、酵素、もしくはこれらの任意の組合せである;
(e)前記ペイロードが第2の抗体である;
(f)経腸的に、経口的に、鼻腔内に、非経口的に、頭蓋内に、皮下に、筋肉内に、皮内に、もしくは静脈内に、もしくはこれらの任意の組合せで投与されるために製剤化される;ならびに/または
(g)前記抗Gal3抗体もしくはその結合性断片が、Gal3のN末端ドメイン、Gal3のN末端、もしくはGal3のタンデムリピートドメイン(TRD)に結合する、請求項5に記載の抗体コンジュゲート。 (a) permeability across the blood-brain barrier when said payload does not independently have the ability to cross said blood-brain barrier or is not conjugated to said anti-Gal3 antibody or binding fragment thereof; is low;
(b) conjugation of the payload to the anti-Gal3 antibody or binding fragment thereof increases the permeability of the payload across the blood-brain barrier by at least 5% compared to the unconjugated payload; , 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 200%, 300%, 400%, or 500%, or any of the above percentages. increase by any increase within the range defined by two;
(c) the permeability of the payload through the blood-brain barrier is 95%, 90%, 80%, 70%, 60%, 50% of the permeability of the antibody conjugate through the blood-brain barrier; lower than 40%, 30%, 20%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, or 1%;
(d) the payload is a cytotoxic payload, a microtubule-interfering agent, a DNA modifier, an Akt inhibitor, a polymerase inhibitor, a detectable moiety, an immunomodulator, an immunomodulator, an immunotoxin, a nucleic acid polymer, an aptamer, a peptide; , a protein, an enzyme, or any combination thereof;
(e) the payload is a second antibody;
(f) administered enterally, orally, intranasally, parenterally, intracranially, subcutaneously, intramuscularly, intradermally, or intravenously, or any combination thereof; and/or
(g) The antibody conjugate according to claim 5 , wherein the anti-Gal3 antibody or binding fragment thereof binds to the N-terminal domain of Gal3, the N-terminus of Gal3, or the tandem repeat domain (TRD) of Gal3 .
前記対象に、請求項1に記載の抗Gal3抗体またはその結合性断片および前記抗Gal3抗体またはその結合性断片にコンジュゲートされたペイロードを含む抗体コンジュゲートを投与することを含み、
前記抗体コンジュゲートが血液脳関門を通過することができる、
方法。 A method of delivering a payload to the central nervous system of a subject in need thereof, the method comprising:
administering to the subject an antibody conjugate comprising the anti-Gal3 antibody or binding fragment thereof of claim 1 and a payload conjugated to the anti-Gal3 antibody or binding fragment thereof,
the antibody conjugate is capable of crossing the blood-brain barrier;
Method.
(b)前記ペイロードが、通常、前記血液脳関門を通過しない;
(c)前記ペイロードを前記抗Gal3抗体もしくはその結合性断片にコンジュゲートすることが、前記血液脳関門を通過する前記ペイロードの透過性を、コンジュゲートされていない前記ペイロードと比較して、少なくとも5%、10%、20%、30%、40%、50%、60%、70%、80%、90%、100%、200%、300%、400%、もしくは500%、もしくは上述のパーセンテージの任意の2つにより定義される範囲内の任意の増加だけ増加させる;
(d)前記血液脳関門を通過する前記ペイロードの透過性が、前記血液脳関門を通過する前記抗体コンジュゲートの透過性の95%、90%、80%、70%、60%、50%、40%、30%、20%、10%、9%、8%、7%、6%、5%、4%、3%、2%、もしくは1%より低い;
(e)前記ペイロードが、細胞傷害性ペイロード、微小管妨害剤、DNA修飾剤、Akt阻害剤、ポリメラーゼ阻害剤、検出可能な部分、免疫調節剤、免疫モジュレーター、免疫毒素、核酸ポリマー、アプタマー、ペプチド、タンパク質、酵素、もしくはこれらの任意の組合せである;または
(f)前記ペイロードが第2の抗体である、請求項7に記載の方法。 (a) administering the antibody conjugate to the subject ;
(b) said payload does not normally cross said blood-brain barrier;
(c) conjugating the payload to the anti-Gal3 antibody or binding fragment thereof increases the permeability of the payload across the blood-brain barrier by at least 5% compared to the unconjugated payload; %, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 200%, 300%, 400%, or 500%, or any of the above percentages. increase by any increment within the range defined by any two;
(d) the permeability of the payload through the blood-brain barrier is 95%, 90%, 80%, 70%, 60%, 50% of the permeability of the antibody conjugate through the blood-brain barrier; lower than 40%, 30%, 20%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, or 1%;
(e) the payload is a cytotoxic payload, a microtubule-interfering agent, a DNA modifier, an Akt inhibitor, a polymerase inhibitor, a detectable moiety, an immunomodulator, an immunomodulator, an immunotoxin, a nucleic acid polymer, an aptamer, a peptide; , a protein, an enzyme, or any combination thereof; or
8. The method of claim 7 , wherein (f) the payload is a second antibody .
前記腫瘍細胞表面マーカーを、請求項1に記載の抗Gal3抗体またはその結合性断片
と接触させることを含み;
前記抗Gal3抗体またはその結合性断片が、Gal3のN末端ドメイン、Gal3のN末端、またはGal3のタンデムリピートドメイン(TRD)に特異的であり、ならびに、
前記腫瘍細胞表面マーカーが、VEGFR1、VEGFR2、VEGFR3、EGFR、PDGFRa、PDGFRb、ErbB2、HGFR(cMet)、TNF sRI、CTLA4、CD47、PD-L1、FGFR1アルファ-IIIb、FGFR1アルファ-IIIc、FGFR2アルファ-IIIc、FGFR3 IIIc、およびFGFR4からなる群から選択される、
方法。 A method of interfering with the interaction of Gal3 with a tumor cell surface marker, the method comprising:
contacting the tumor cell surface marker with the anti-Gal3 antibody or binding fragment thereof of claim 1 ;
the anti-Gal3 antibody or binding fragment thereof is specific for the N-terminal domain of Gal3, the N-terminus of Gal3, or the tandem repeat domain (TRD) of Gal3, and
The tumor cell surface markers include VEGFR1, VEGFR2, VEGFR3, EGFR, PDGFRa, PDGFRb, ErbB2, HGFR (cMet), TNF sRI, CTLA4, CD47, PD-L1, FGFR1 alpha-IIIb, FGFR1 alpha-IIIc, FGFR2 alpha- selected from the group consisting of IIIc, FGFR3 IIIc, and FGFR4,
Method.
(a)Gal3タンパク質を、Gal3に選択的に結合する請求項1に記載の抗Gal3抗体またはその結合性断片と接触させ、それにより、Gal3-抗体複合体を形成させること;
(b)前記Gal3-抗体複合体を前記TGF-b受容体タンパク質と接触させること;
(c)未結合のTGF-b受容体タンパク質を除去すること;および
(d)前記Gal3-抗体複合体に結合したTGF-b受容体タンパク質を検出することを含み;
前記抗Gal3抗体またはその結合性断片が、(d)において前記TGF-b受容体タンパク質が検出されない場合に、Gal3と前記TGF-b受容体との相互作用を妨害する能力を有する、
方法。 1. A method of identifying an antibody or binding fragment capable of interfering with the interaction of Gal3 with a TGF-b receptor, the method comprising:
(a) contacting the Gal3 protein with the anti-Gal3 antibody or binding fragment thereof according to claim 1 that selectively binds to Gal3, thereby forming a Gal3-antibody complex;
(b) contacting the Gal3-antibody complex with the TGF-b receptor protein;
(c) removing unbound TGF-b receptor protein; and (d) detecting TGF-b receptor protein bound to the Gal3-antibody complex;
the anti-Gal3 antibody or binding fragment thereof has the ability to interfere with the interaction between Gal3 and the TGF-b receptor when the TGF-b receptor protein is not detected in (d);
Method.
2)配列番号137内のVH-CDR1、VH-CDR2、VH-CDR3であるVH-CDR1、VH-CDR2、VH-CDR3および配列番号162内のVL-CDR1、VL-CDR2、VL-CDR3であるVL-CDR1、VL-CDR2、VL-CDR3;
3)配列番号138内のVH-CDR1、VH-CDR2、VH-CDR3であるVH-CDR1、VH-CDR2、VH-CDR3および配列番号163内のVL-CDR1、VL-CDR2、VL-CDR3であるVL-CDR1、VL-CDR2、VL-CDR3;
4)配列番号139内のVH-CDR1、VH-CDR2、VH-CDR3であるVH-CDR1、VH-CDR2、VH-CDR3および配列番号164内のVL-CDR1、VL-CDR2、VL-CDR3であるVL-CDR1、VL-CDR2、VL-CDR3;
5)配列番号140内のVH-CDR1、VH-CDR2、VH-CDR3であるVH-CDR1、VH-CDR2、VH-CDR3および配列番号165内のVL-CDR1、VL-CDR2、VL-CDR3であるVL-CDR1、VL-CDR2、VL-CDR3;
6)配列番号141内のVH-CDR1、VH-CDR2、VH-CDR3であるVH-CDR1、VH-CDR2、VH-CDR3および配列番号166内のVL-CDR1、VL-CDR2、VL-CDR3であるVL-CDR1、VL-CDR2、VL-CDR3;
7)配列番号142内のVH-CDR1、VH-CDR2、VH-CDR3であるVH-CDR1、VH-CDR2、VH-CDR3および配列番号167内のVL-CDR1、VL-CDR2、VL-CDR3であるVL-CDR1、VL-CDR2、VL-CDR3;
8)配列番号143内のVH-CDR1、VH-CDR2、VH-CDR3であるVH-CDR1、VH-CDR2、VH-CDR3および配列番号168内のVL-CDR1、VL-CDR2、VL-CDR3であるVL-CDR1、VL-CDR2、VL-CDR3;
9)配列番号144内のVH-CDR1、VH-CDR2、VH-CDR3であるVH-CDR1、VH-CDR2、VH-CDR3および配列番号169内のVL-CDR1、VL-CDR2、VL-CDR3であるVL-CDR1、VL-CDR2、VL-CDR3;
10)配列番号145内のVH-CDR1、VH-CDR2、VH-CDR3であるVH-CDR1、VH-CDR2、VH-CDR3および配列番号170内のVL-CDR1、VL-CDR2、VL-CDR3であるVL-CDR1、VL-CDR2、VL-CDR3;
11)配列番号139内のVH-CDR1、VH-CDR2、VH-CDR3であるVH-CDR1、VH-CDR2、VH-CDR3および配列番号171内のVL-CDR1、VL-CDR2、VL-CDR3であるVL-CDR1、VL-CDR2、VL-CDR3;
12)配列番号146内のVH-CDR1、VH-CDR2、VH-CDR3であるVH-CDR1、VH-CDR2、VH-CDR3および配列番号172内のVL-CDR1、VL-CDR2、VL-CDR3であるVL-CDR1、VL-CDR2、VL-CDR3;
13)配列番号147内のVH-CDR1、VH-CDR2、VH-CDR3であるVH-CDR1、VH-CDR2、VH-CDR3および配列番号173内のVL-CDR1、VL-CDR2、VL-CDR3であるVL-CDR1、VL-CDR2、VL-CDR3;
14)配列番号148内のVH-CDR1、VH-CDR2、VH-CDR3であるVH-CDR1、VH-CDR2、VH-CDR3および配列番号174内のVL-CDR1、VL-CDR2、VL-CDR3であるVL-CDR1、VL-CDR2、VL-CDR3;
15)配列番号149内のVH-CDR1、VH-CDR2、VH-CDR3であるVH-CDR1、VH-CDR2、VH-CDR3および配列番号175内のVL-CDR1、VL-CDR2、VL-CDR3であるVL-CDR1、VL-CDR2、VL-CDR3;
16)配列番号150内のVH-CDR1、VH-CDR2、VH-CDR3であるVH-CDR1、VH-CDR2、VH-CDR3および配列番号176内のVL-CDR1、VL-CDR2、VL-CDR3であるVL-CDR1、VL-CDR2、VL-CDR3;
17)配列番号151内のVH-CDR1、VH-CDR2、VH-CDR3であるVH-CDR1、VH-CDR2、VH-CDR3および配列番号177内のVL-CDR1、VL-CDR2、VL-CDR3であるVL-CDR1、VL-CDR2、VL-CDR3;
18)配列番号152内のVH-CDR1、VH-CDR2、VH-CDR3であるVH-CDR1、VH-CDR2、VH-CDR3および配列番号178内のVL-CDR1、VL-CDR2、VL-CDR3であるVL-CDR1、VL-CDR2、VL-CDR3;
19)配列番号153内のVH-CDR1、VH-CDR2、VH-CDR3であるVH-CDR1、VH-CDR2、VH-CDR3および配列番号179内のVL-CDR
1、VL-CDR2、VL-CDR3であるVL-CDR1、VL-CDR2、VL-CDR3;
20)配列番号154内のVH-CDR1、VH-CDR2、VH-CDR3であるVH-CDR1、VH-CDR2、VH-CDR3および配列番号180内のVL-CDR1、VL-CDR2、VL-CDR3であるVL-CDR1、VL-CDR2、VL-CDR3;
21)配列番号155内のVH-CDR1、VH-CDR2、VH-CDR3であるVH-CDR1、VH-CDR2、VH-CDR3および配列番号181内のVL-CDR1、VL-CDR2、VL-CDR3であるVL-CDR1、VL-CDR2、VL-CDR3;
22)配列番号156内のVH-CDR1、VH-CDR2、VH-CDR3であるVH-CDR1、VH-CDR2、VH-CDR3および配列番号182内のVL-CDR1、VL-CDR2、VL-CDR3であるVL-CDR1、VL-CDR2、VL-CDR3;
23)配列番号157内のVH-CDR1、VH-CDR2、VH-CDR3であるVH-CDR1、VH-CDR2、VH-CDR3および配列番号183内のVL-CDR1、VL-CDR2、VL-CDR3であるVL-CDR1、VL-CDR2、VL-CDR3;
24)配列番号155内のVH-CDR1、VH-CDR2、VH-CDR3であるVH-CDR1、VH-CDR2、VH-CDR3および配列番号184内のVL-CDR1、VL-CDR2、VL-CDR3であるVL-CDR1、VL-CDR2、VL-CDR3;
25)配列番号158内のVH-CDR1、VH-CDR2、VH-CDR3であるVH-CDR1、VH-CDR2、VH-CDR3および配列番号185内のVL-CDR1、VL-CDR2、VL-CDR3であるVL-CDR1、VL-CDR2、VL-CDR3;
26)配列番号159内のVH-CDR1、VH-CDR2、VH-CDR3であるVH-CDR1、VH-CDR2、VH-CDR3および配列番号186内のVL-CDR1、VL-CDR2、VL-CDR3であるVL-CDR1、VL-CDR2、VL-CDR3;
27)配列番号160内のVH-CDR1、VH-CDR2、VH-CDR3であるVH-CDR1、VH-CDR2、VH-CDR3および配列番号187内のVL-CDR1、VL-CDR2、VL-CDR3であるVL-CDR1、VL-CDR2、VL-CDR3;
28)配列番号256内のV H -CDR1、V H -CDR2、V H -CDR3であるV H -CDR1、V H -CDR2、V H -CDR3および配列番号258内のV L -CDR1、V L -CDR2、V L -CDR3であるV L -CDR1、V L -CDR2、V L -CDR3;
29)配列番号257内のV H -CDR1、V H -CDR2、V H -CDR3であるV H -CDR1、V H -CDR2、V H -CDR3および配列番号259内のV L -CDR1、V L -CDR2、V L -CDR3であるV L -CDR1、V L -CDR2、V L -CDR3;
30)配列番号756内のVH-CDR1、VH-CDR2、VH-CDR3であるVH-CDR1、VH-CDR2、VH-CDR3および配列番号784内のVL-CDR1、VL-CDR2、VL-CDR3であるVL-CDR1、VL-CDR2、VL-CDR3;
31)配列番号757内のVH-CDR1、VH-CDR2、VH-CDR3であるVH-CDR1、VH-CDR2、VH-CDR3および配列番号785内のVL-CDR1、VL-CDR2、VL-CDR3であるVL-CDR1、VL-CDR2、VL-CDR3;
32)配列番号758内のVH-CDR1、VH-CDR2、VH-CDR3であるVH-CDR1、VH-CDR2、VH-CDR3および配列番号786内のVL-CDR1、VL-CDR2、VL-CDR3であるVL-CDR1、VL-CDR2、VL-CDR3;
33)配列番号759内のVH-CDR1、VH-CDR2、VH-CDR3であるVH-CDR1、VH-CDR2、VH-CDR3および配列番号787内のVL-CDR1、VL-CDR2、VL-CDR3であるVL-CDR1、VL-CDR2、VL-CDR3;
34)配列番号760内のVH-CDR1、VH-CDR2、VH-CDR3であるVH-CDR1、VH-CDR2、VH-CDR3および配列番号788内のVL-CDR1、VL-CDR2、VL-CDR3であるVL-CDR1、VL-CDR2、VL-CDR3;
35)配列番号761内のVH-CDR1、VH-CDR2、VH-CDR3であるVH-CDR1、VH-CDR2、VH-CDR3および配列番号789内のVL-CDR1、VL-CDR2、VL-CDR3であるVL-CDR1、VL-CDR2、VL-CDR3;
36)配列番号762内のVH-CDR1、VH-CDR2、VH-CDR3であるVH-CDR1、VH-CDR2、VH-CDR3および配列番号790内のVL-CDR1、VL-CDR2、VL-CDR3であるVL-CDR1、VL-CDR2、VL-CDR3;
37)配列番号763内のVH-CDR1、VH-CDR2、VH-CDR3であるVH-CDR1、VH-CDR2、VH-CDR3および配列番号791内のVL-CDR1、VL-CDR2、VL-CDR3であるVL-CDR1、VL-CDR2、VL-CDR3;
38)配列番号764内のVH-CDR1、VH-CDR2、VH-CDR3であるVH-CDR1、VH-CDR2、VH-CDR3および配列番号792内のVL-CDR1、VL-CDR2、VL-CDR3であるVL-CDR1、VL-CDR2、VL-CDR3;
39)配列番号765内のVH-CDR1、VH-CDR2、VH-CDR3であるVH-CDR1、VH-CDR2、VH-CDR3および配列番号793内のVL-CDR1、VL-CDR2、VL-CDR3であるVL-CDR1、VL-CDR2、VL-CDR3;
40)配列番号766内のVH-CDR1、VH-CDR2、VH-CDR3であるVH-CDR1、VH-CDR2、VH-CDR3および配列番号794内のVL-CDR1、VL-CDR2、VL-CDR3であるVL-CDR1、VL-CDR2、VL-CDR3;
41)配列番号767内のVH-CDR1、VH-CDR2、VH-CDR3であるVH-CDR1、VH-CDR2、VH-CDR3および配列番号795内のVL-CDR1、VL-CDR2、VL-CDR3であるVL-CDR1、VL-CDR2、VL-CDR3;
42)配列番号768内のVH-CDR1、VH-CDR2、VH-CDR3であるVH-CDR1、VH-CDR2、VH-CDR3および配列番号796内のVL-CDR1、VL-CDR2、VL-CDR3であるVL-CDR1、VL-CDR2、VL-CDR3;
43)配列番号769内のVH-CDR1、VH-CDR2、VH-CDR3であるVH-CDR1、VH-CDR2、VH-CDR3および配列番号797内のVL-CDR1、VL-CDR2、VL-CDR3であるVL-CDR1、VL-CDR2、VL-CDR3;
44)配列番号770内のVH-CDR1、VH-CDR2、VH-CDR3であるVH-CDR1、VH-CDR2、VH-CDR3および配列番号798内のVL-CDR
1、VL-CDR2、VL-CDR3であるVL-CDR1、VL-CDR2、VL-CDR3;
45)配列番号771内のVH-CDR1、VH-CDR2、VH-CDR3であるVH-CDR1、VH-CDR2、VH-CDR3および配列番号799内のVL-CDR1、VL-CDR2、VL-CDR3であるVL-CDR1、VL-CDR2、VL-CDR3;
46)配列番号772内のVH-CDR1、VH-CDR2、VH-CDR3であるVH-CDR1、VH-CDR2、VH-CDR3および配列番号800内のVL-CDR1、VL-CDR2、VL-CDR3であるVL-CDR1、VL-CDR2、VL-CDR3;
47)配列番号773内のVH-CDR1、VH-CDR2、VH-CDR3であるVH-CDR1、VH-CDR2、VH-CDR3および配列番号801内のVL-CDR1、VL-CDR2、VL-CDR3であるVL-CDR1、VL-CDR2、VL-CDR3;
48)配列番号774内のVH-CDR1、VH-CDR2、VH-CDR3であるVH-CDR1、VH-CDR2、VH-CDR3および配列番号802内のVL-CDR1、VL-CDR2、VL-CDR3であるVL-CDR1、VL-CDR2、VL-CDR3;
49)配列番号775内のVH-CDR1、VH-CDR2、VH-CDR3であるVH-CDR1、VH-CDR2、VH-CDR3および配列番号803内のVL-CDR1、VL-CDR2、VL-CDR3であるVL-CDR1、VL-CDR2、VL-CDR3;
50)配列番号776内のVH-CDR1、VH-CDR2、VH-CDR3であるVH-CDR1、VH-CDR2、VH-CDR3および配列番号804内のVL-CDR1、VL-CDR2、VL-CDR3であるVL-CDR1、VL-CDR2、VL-CDR3;
51)配列番号777内のVH-CDR1、VH-CDR2、VH-CDR3であるVH-CDR1、VH-CDR2、VH-CDR3および配列番号805内のVL-CDR1、VL-CDR2、VL-CDR3であるVL-CDR1、VL-CDR2、VL-CDR3;
52)配列番号778内のVH-CDR1、VH-CDR2、VH-CDR3であるVH-CDR1、VH-CDR2、VH-CDR3および配列番号806内のVL-CDR1、VL-CDR2、VL-CDR3であるVL-CDR1、VL-CDR2、VL-CDR3;
53)配列番号779内のVH-CDR1、VH-CDR2、VH-CDR3であるVH-CDR1、VH-CDR2、VH-CDR3および配列番号807内のVL-CDR1、VL-CDR2、VL-CDR3であるVL-CDR1、VL-CDR2、VL-CDR3;
54)配列番号780内のVH-CDR1、VH-CDR2、VH-CDR3であるVH-CDR1、VH-CDR2、VH-CDR3および配列番号808内のVL-CDR1、VL-CDR2、VL-CDR3であるVL-CDR1、VL-CDR2、VL-CDR3;
55)配列番号781内のVH-CDR1、VH-CDR2、VH-CDR3であるVH-CDR1、VH-CDR2、VH-CDR3および配列番号809内のVL-CDR1、VL-CDR2、VL-CDR3であるVL-CDR1、VL-CDR2、VL-CDR3;
56)配列番号782内のVH-CDR1、VH-CDR2、VH-CDR3であるVH-CDR1、VH-CDR2、VH-CDR3および配列番号810内のVL-CDR1、VL-CDR2、VL-CDR3であるVL-CDR1、VL-CDR2、VL-CDR3;または
57)配列番号783内のVH-CDR1、VH-CDR2、VH-CDR3であるVH-CDR1、VH-CDR2、VH-CDR3および配列番号811内のVL-CDR1、VL-CDR2、VL-CDR3であるVL-CDR1、VL-CDR2、VL-CDR3を含む、請求項1に記載の抗Gal3抗体またはその結合性断片。 1 ) V H -CDR1, V H -CDR2, V H -CDR3 which are V H -CDR1, V H -CDR2, V H -CDR3 in SEQ ID NO: 136 and V L -CDR1, V L in SEQ ID NO: 161 -CDR2, V L -CDR3 , V L -CDR1, V L -CDR2, V L -CDR3;
2) V H -CDR1, V H -CDR2, V H -CDR3 which are V H -CDR1, V H -CDR2, V H -CDR3 in SEQ ID NO: 137 and V L -CDR1, V L in SEQ ID NO: 162 -CDR2, V L -CDR3 , V L -CDR1, V L -CDR2, V L -CDR3;
3) V H -CDR1, V H -CDR2, V H -CDR3 which are V H -CDR1, V H -CDR2, V H -CDR3 in SEQ ID NO: 138 and V L -CDR1, V L in SEQ ID NO: 163 -CDR2, V L -CDR3 , V L -CDR1, V L -CDR2, V L -CDR3;
4) V H -CDR1, V H -CDR2, V H -CDR3 which are V H -CDR1, V H -CDR2, V H -CDR3 in SEQ ID NO: 139 and V L -CDR1, V L in SEQ ID NO: 164 -CDR2, V L -CDR3 , V L -CDR1, V L -CDR2, V L -CDR3;
5 ) V H -CDR1, V H -CDR2, V H -CDR3 which are V H -CDR1, V H -CDR2, V H -CDR3 in SEQ ID NO: 140 and V L -CDR1, V in SEQ ID NO: 165 V L -CDR1, V L -CDR2 , V L -CDR3 which are L -CDR2, V L -CDR3;
6 ) V H -CDR1, V H -CDR2, V H -CDR3 which are V H -CDR1, V H -CDR2, V H -CDR3 in SEQ ID NO: 141 and V L -CDR1, V L in SEQ ID NO: 166 -CDR2, V L -CDR3 , V L -CDR1, V L -CDR2, V L -CDR3;
7 ) V H -CDR1, V H -CDR2, V H -CDR3 which are V H -CDR1, V H -CDR2, V H -CDR3 in SEQ ID NO: 142 and V L -CDR1, V L in SEQ ID NO: 167 -CDR2, V L -CDR3 , V L -CDR1, V L -CDR2, V L -CDR3;
8 ) V H -CDR1, V H -CDR2, V H -CDR3 which are V H -CDR1, V H -CDR2, V H -CDR3 in SEQ ID NO: 143 and V L -CDR1, V L in SEQ ID NO: 168 -CDR2, V L -CDR3 , V L -CDR1, V L -CDR2, V L -CDR3;
9 ) V H -CDR1, V H -CDR2, V H -CDR3 which are V H -CDR1, V H -CDR2, V H -CDR3 in SEQ ID NO: 144 and V L -CDR1, V L in SEQ ID NO: 169 -CDR2, V L -CDR3 , V L -CDR1, V L -CDR2, V L -CDR3;
10 ) V H -CDR1, V H -CDR2, V H -CDR3 which are V H -CDR1, V H -CDR2, V H -CDR3 in SEQ ID NO: 145 and V L -CDR1, V in SEQ ID NO: 170 V L -CDR1, V L -CDR2 , V L -CDR3 which are L -CDR2, V L -CDR3;
11) VH-CDR1, VH-CDR2, VH-CDR3 which are VH-CDR1, VH-CDR2, VH-CDR3 in SEQ ID NO: 139 and VL-CDR1, VL-CDR2, VL-CDR3 in SEQ ID NO: 171 VL-CDR1, VL-CDR2, VL-CDR3;
12) V H -CDR1, V H -CDR2, V H -CDR3 which are V H -CDR1, V H -CDR2, V H -CDR3 in SEQ ID NO: 146 and V L -CDR1, V L in SEQ ID NO: 172 -CDR2, V L -CDR3 , V L -CDR1, V L -CDR2, V L -CDR3;
13) V H -CDR1, V H -CDR2, V H -CDR3 which are V H -CDR1, V H -CDR2, V H -CDR3 in SEQ ID NO: 147 and V L -CDR1 in SEQ ID NO: 173 , V L -CDR1, V L -CDR2, V L -CDR3 which are V L -CDR2, V L -CDR3;
14) V H -CDR1, V H -CDR2, V H -CDR3 which are V H -CDR1, V H -CDR2, V H -CDR3 in SEQ ID NO : 148 and V L -CDR1, V L in SEQ ID NO: 174 -CDR2, V L -CDR3 , V L -CDR1, V L -CDR2, V L -CDR3;
15) V H -CDR1, V H -CDR2, V H -CDR3 which are V H -CDR1, V H -CDR2, V H -CDR3 in SEQ ID NO : 149 and V L -CDR1, V L in SEQ ID NO: 175 -CDR2, V L -CDR3 , V L -CDR1, V L -CDR2, V L -CDR3;
16) V H -CDR1, V H -CDR2, V H -CDR3 which are V H -CDR1, V H -CDR2, V H -CDR3 in SEQ ID NO : 150 and V L -CDR1, V L in SEQ ID NO: 176 -CDR2, V L -CDR3 , V L -CDR1, V L -CDR2, V L -CDR3;
17) V H -CDR1, V H -CDR2 , V H -CDR3 which are V H -CDR1, V H -CDR2, V H -CDR3 in SEQ ID NO: 151 and V L -CDR1, V L in SEQ ID NO: 177 -CDR2, V L -CDR3 , V L -CDR1, V L -CDR2, V L -CDR3;
18) V H -CDR1, V H -CDR2, V H -CDR3 which are V H -CDR1, V H -CDR2, V H -CDR3 in SEQ ID NO : 152 and V L -CDR1, V L in SEQ ID NO: 178 -CDR2, V L -CDR3 , V L -CDR1, V L -CDR2, V L -CDR3;
19) V H -CDR1 , V H -CDR2, V H -CDR3 in SEQ ID NO: 153 and V L -CDR in SEQ ID NO : 179
1, V L -CDR2, V L -CDR3, V L -CDR1, V L -CDR2 , V L -CDR3;
20) V H -CDR1, V H -CDR2, V H -CDR3 which are V H -CDR1, V H -CDR2, V H -CDR3 in SEQ ID NO : 154 and V L -CDR1, V L in SEQ ID NO: 180 -CDR2, V L -CDR3 , V L -CDR1, V L -CDR2, V L -CDR3;
21) V H -CDR1, V H -CDR2, V H -CDR3 which are V H -CDR1, V H -CDR2, V H -CDR3 in SEQ ID NO: 155 and V L -CDR1, V L in SEQ ID NO: 181 -CDR2, V L -CDR3 , V L -CDR1, V L -CDR2, V L -CDR3;
22) V H -CDR1, V H -CDR2, V H -CDR3 which are V H -CDR1, V H -CDR2, V H -CDR3 in SEQ ID NO : 156 and V L -CDR1, V L in SEQ ID NO: 182 -CDR2, V L -CDR3 , V L -CDR1, V L -CDR2, V L -CDR3;
23) V H -CDR1, V H -CDR2, V H -CDR3 which are V H -CDR1, V H -CDR2, V H -CDR3 in SEQ ID NO : 157 and V L -CDR1, V L in SEQ ID NO: 183 -CDR2, V L -CDR3 , V L -CDR1, V L -CDR2, V L -CDR3;
24) V H -CDR1, V H -CDR2, V H -CDR3 which are V H -CDR1, V H -CDR2, V H -CDR3 in SEQ ID NO : 155 and V L -CDR1, V L in SEQ ID NO: 184 -CDR2, V L -CDR3 , V L -CDR1, V L -CDR2, V L -CDR3;
25) V H -CDR1, V H -CDR2, V H -CDR3 which are V H -CDR1, V H -CDR2, V H -CDR3 in SEQ ID NO : 158 and V L -CDR1, V L in SEQ ID NO: 185 -CDR2, V L -CDR3 , V L -CDR1, V L -CDR2, V L -CDR3;
26) V H -CDR1, V H -CDR2, V H -CDR3 which are V H -CDR1, V H -CDR2, V H -CDR3 in SEQ ID NO : 159 and V L -CDR1, V L in SEQ ID NO: 186 -CDR2, V L -CDR3 , V L -CDR1, V L -CDR2, V L -CDR3;
27) V H -CDR1, V H -CDR2, V H -CDR3 which are V H -CDR1, V H -CDR2, V H -CDR3 in SEQ ID NO : 160 and V L -CDR1, V L in SEQ ID NO: 187 -CDR2, V L -CDR3 , V L -CDR1, V L -CDR2, V L -CDR3;
28) V H -CDR1, V H -CDR2, V H -CDR3 which are V H -CDR1, V H -CDR2, V H -CDR3 in SEQ ID NO: 256 and V L -CDR1, V L in SEQ ID NO: 258 -CDR2, V L -CDR3, V L -CDR1, V L -CDR2, V L -CDR3;
29) V H -CDR1, V H -CDR2, V H -CDR3 which are V H -CDR1, V H -CDR2, V H -CDR3 in SEQ ID NO: 257 and V L -CDR1, V L in SEQ ID NO: 259 -CDR2, V L -CDR3, V L -CDR1, V L -CDR2, V L -CDR3;
30 ) V H -CDR1, V H -CDR2, V H -CDR3 which are V H -CDR1, V H -CDR2, V H -CDR3 in SEQ ID NO: 756 and V L -CDR1, V L in SEQ ID NO: 784 -CDR2, V L -CDR3 , V L -CDR1, V L -CDR2, V L -CDR3;
31 ) V H -CDR1, V H -CDR2, V H -CDR3 which are V H -CDR1, V H -CDR2, V H -CDR3 in SEQ ID NO: 757 and V L -CDR1, V L in SEQ ID NO: 785 -CDR2, V L -CDR3 , V L -CDR1, V L -CDR2, V L -CDR3;
3 2 ) V H -CDR1, V H -CDR2, V H -CDR3 which are V H -CDR1, V H -CDR2, V H -CDR3 in SEQ ID NO: 758 and V L -CDR1, V in SEQ ID NO: 786 V L -CDR1, V L -CDR2, V L -CDR3 which are L -CDR2, V L -CDR3;
3 3 ) V H -CDR1, V H -CDR2, V H -CDR3 in SEQ ID NO: 759 and V L -CDR1 , V in SEQ ID NO : 787 V L -CDR1, V L -CDR2 , V L -CDR3 which are L -CDR2, V L -CDR3;
3 4 ) V H -CDR1, V H -CDR2, V H -CDR3 in SEQ ID NO: 760 and V L -CDR1 , V in SEQ ID NO : 788 V L -CDR1, V L -CDR2 , V L -CDR3 which are L -CDR2, V L -CDR3;
3 5 ) V H -CDR1, V H -CDR2, V H -CDR3 which are V H -CDR1, V H -CDR2, V H -CDR3 in SEQ ID NO: 761 and V L -CDR1, V in SEQ ID NO: 789 V L -CDR1, V L -CDR2 , V L -CDR3 which are L -CDR2, V L -CDR3;
3 6 ) V H -CDR1, V H -CDR2, V H -CDR3 which are V H -CDR1, V H -CDR2, V H -CDR3 in SEQ ID NO: 762 and V L -CDR1, V in SEQ ID NO: 790 V L -CDR1, V L -CDR2 , V L -CDR3 which are L -CDR2, V L -CDR3;
3 7 ) V H -CDR1, V H -CDR2, V H -CDR3 which are V H -CDR1, V H -CDR2, V H -CDR3 in SEQ ID NO: 763 and V L -CDR1, V in SEQ ID NO: 791 V L -CDR1, V L -CDR2 , V L -CDR3 which are L -CDR2, V L -CDR3;
3 8 ) V H -CDR1, V H -CDR2, V H -CDR3 in SEQ ID NO: 764 and V L -CDR1 , V in SEQ ID NO : 792 V L -CDR1, V L -CDR2 , V L -CDR3 which are L -CDR2, V L -CDR3;
39 ) V H -CDR1, V H -CDR2, V H -CDR3 which are V H -CDR1, V H -CDR2, V H -CDR3 in SEQ ID NO: 765 and V L -CDR1, V in SEQ ID NO: 793 V L -CDR1, V L -CDR2 , V L -CDR3 which are L -CDR2, V L -CDR3;
40 ) V H -CDR1, V H -CDR2, V H -CDR3 in SEQ ID NO: 766 and V L -CDR1, V L in SEQ ID NO : 794 -CDR2, V L -CDR3 , V L -CDR1, V L -CDR2, V L -CDR3;
41 ) V H -CDR1, V H -CDR2, V H -CDR3 which are V H -CDR1, V H -CDR2, V H -CDR3 in SEQ ID NO: 767 and V L -CDR1, V L in SEQ ID NO: 795 -CDR2, V L -CDR3 , V L -CDR1, V L -CDR2, V L -CDR3;
4 2 ) V H -CDR1, V H -CDR2, V H -CDR3 in SEQ ID NO: 768 and V L -CDR1 , V in SEQ ID NO : 796 V L -CDR1, V L -CDR2 , V L -CDR3 which are L -CDR2, V L -CDR3;
4 3 ) V H -CDR1, V H -CDR2, V H -CDR3 in SEQ ID NO: 769 and V L -CDR1 , V in SEQ ID NO : 797 V L -CDR1, V L -CDR2 , V L -CDR3 which are L -CDR2, V L -CDR3;
4 4 ) V H -CDR1, V H -CDR2 , V H -CDR3 in SEQ ID NO : 770 and V L -CDR in SEQ ID NO: 798
1, V L -CDR2, V L -CDR3, V L -CDR1, V L -CDR2 , V L -CDR3;
4 5 ) V H -CDR1, V H -CDR2, V H -CDR3 in SEQ ID NO: 771 and V L -CDR1 , V in SEQ ID NO: 799 V L -CDR1, V L -CDR2 , V L -CDR3 which are L -CDR2, V L -CDR3;
4 6 ) V H -CDR1, V H -CDR2, V H -CDR3 which are V H -CDR1, V H -CDR2, V H -CDR3 in SEQ ID NO: 772 and V L -CDR1, V in SEQ ID NO: 800 V L -CDR1, V L -CDR2, V L -CDR3 which are L -CDR2, V L -CDR3;
4 7 ) V H -CDR1, V H -CDR2, V H -CDR3 which are V H -CDR1, V H -CDR2, V H -CDR3 in SEQ ID NO: 773 and V L -CDR1, V in SEQ ID NO: 801 V L -CDR1, V L -CDR2 , V L -CDR3 which are L -CDR2, V L -CDR3;
4 8 ) V H -CDR1, V H -CDR2, V H -CDR3 which are V H -CDR1, V H -CDR2, V H -CDR3 in SEQ ID NO: 774 and V L -CDR1, V in SEQ ID NO: 802 V L -CDR1, V L -CDR2 , V L -CDR3 which are L -CDR2, V L -CDR3;
49 ) V H -CDR1, V H -CDR2, V H -CDR3 which are V H -CDR1, V H -CDR2, V H -CDR3 in SEQ ID NO: 775 and V L -CDR1, V in SEQ ID NO: 803 V L -CDR1, V L -CDR2 , V L -CDR3 which are L -CDR2, V L -CDR3;
50 ) V H -CDR1, V H -CDR2, V H -CDR3 which are V H -CDR1, V H -CDR2, V H -CDR3 in SEQ ID NO: 776 and V L -CDR1, V L in SEQ ID NO: 804 -CDR2, V L -CDR3 , V L -CDR1, V L -CDR2, V L -CDR3;
51 ) V H -CDR1, V H -CDR2, V H -CDR3 which are V H -CDR1, V H -CDR2, V H -CDR3 in SEQ ID NO: 777 and V L -CDR1, V L in SEQ ID NO: 805 -CDR2, V L -CDR3 , V L -CDR1, V L -CDR2, V L -CDR3;
5 2 ) V H -CDR1, V H -CDR2, V H -CDR3 which are V H -CDR1, V H -CDR2, V H -CDR3 in SEQ ID NO: 778 and V L -CDR1, V in SEQ ID NO: 806 V L -CDR1, V L -CDR2, V L -CDR3 which are L -CDR2, V L -CDR3;
5 3 ) V H -CDR1, V H -CDR2, V H -CDR3 which are V H -CDR1, V H -CDR2, V H -CDR3 in SEQ ID NO: 779 and V L -CDR1, V in SEQ ID NO: 807 V L -CDR1, V L -CDR2 , V L -CDR3 which are L -CDR2, V L -CDR3;
5 4 ) V H -CDR1, V H -CDR2, V H -CDR3 which are V H -CDR1, V H -CDR2, V H -CDR3 in SEQ ID NO: 780 and V L -CDR1, V in SEQ ID NO: 808 V L -CDR1, V L -CDR2 , V L -CDR3 which are L -CDR2, V L -CDR3;
5 5 ) V H -CDR1, V H -CDR2, V H -CDR3 which are V H -CDR1, V H -CDR2, V H -CDR3 in SEQ ID NO: 781 and V L -CDR1, V in SEQ ID NO: 809 V L -CDR1, V L -CDR2 , V L -CDR3 which are L -CDR2, V L -CDR3;
5 6 ) V H -CDR1, V H -CDR2, V H -CDR3 which are V H -CDR1, V H -CDR2, V H -CDR3 in SEQ ID NO: 782 and V L -CDR1, V in SEQ ID NO: 810 V L -CDR1, V L -CDR2, V L -CDR3 which is L -CDR2, V L -CDR3; or 57 ) which is V H -CDR1, V H -CDR2, V H -CDR3 in SEQ ID NO: 783 V H -CDR1, V H -CDR2, V H -CDR3 and V L -CDR1, V L -CDR2, V L -CDR3 which are V L -CDR1 , V L -CDR2, V L -CDR3 in SEQ ID NO: 811 The anti-Gal3 antibody or binding fragment thereof according to claim 1 , comprising:
2)配列番号137の重鎖可変領域および配列番号162の軽鎖可変領域;
3)配列番号138の重鎖可変領域および配列番号163の軽鎖可変領域;
4)配列番号139の重鎖可変領域および配列番号164の軽鎖可変領域;
5)配列番号140の重鎖可変領域および配列番号165の軽鎖可変領域;
6)配列番号141の重鎖可変領域および配列番号166の軽鎖可変領域;
7)配列番号142の重鎖可変領域および配列番号167の軽鎖可変領域;
8)配列番号143の重鎖可変領域および配列番号168の軽鎖可変領域;
9)配列番号144の重鎖可変領域および配列番号169の軽鎖可変領域;
10)配列番号145の重鎖可変領域および配列番号170の軽鎖可変領域;
11)配列番号139の重鎖可変領域および配列番号171の軽鎖可変領域;
12)配列番号146の重鎖可変領域および配列番号172の軽鎖可変領域;
13)配列番号147の重鎖可変領域および配列番号173の軽鎖可変領域;
14)配列番号148の重鎖可変領域および配列番号174の軽鎖可変領域;
15)配列番号149の重鎖可変領域および配列番号175の軽鎖可変領域;
16)配列番号150の重鎖可変領域および配列番号176の軽鎖可変領域;
17)配列番号151の重鎖可変領域および配列番号177の軽鎖可変領域;
18)配列番号152の重鎖可変領域および配列番号178の軽鎖可変領域;
19)配列番号153の重鎖可変領域および配列番号179の軽鎖可変領域;
20)配列番号154の重鎖可変領域および配列番号180の軽鎖可変領域;
21)配列番号155の重鎖可変領域および配列番号181の軽鎖可変領域;
22)配列番号156の重鎖可変領域および配列番号182の軽鎖可変領域;
23)配列番号157の重鎖可変領域および配列番号183の軽鎖可変領域;
24)配列番号155の重鎖可変領域および配列番号184の軽鎖可変領域;
25)配列番号158の重鎖可変領域および配列番号185の軽鎖可変領域;
26)配列番号159の重鎖可変領域および配列番号186の軽鎖可変領域;
27)配列番号160の重鎖可変領域および配列番号187の軽鎖可変領域;
28)配列番号256の重鎖可変領域および配列番号258の軽鎖可変領域;
29)配列番号257の重鎖可変領域および配列番号259の軽鎖可変領域;
30)配列番号756の重鎖可変領域および配列番号784の軽鎖可変領域;
31)配列番号757の重鎖可変領域および配列番号785の軽鎖可変領域;
32)配列番号758の重鎖可変領域および配列番号786の軽鎖可変領域;
33)配列番号759の重鎖可変領域および配列番号787の軽鎖可変領域;
34)配列番号760の重鎖可変領域および配列番号788の軽鎖可変領域;
35)配列番号761の重鎖可変領域および配列番号789の軽鎖可変領域;
36)配列番号762の重鎖可変領域および配列番号790の軽鎖可変領域;
37)配列番号763の重鎖可変領域および配列番号791の軽鎖可変領域;
38)配列番号764の重鎖可変領域および配列番号792の軽鎖可変領域;
39)配列番号765の重鎖可変領域および配列番号793の軽鎖可変領域;
40)配列番号766の重鎖可変領域および配列番号794の軽鎖可変領域;
41)配列番号767の重鎖可変領域および配列番号795の軽鎖可変領域;
42)配列番号768の重鎖可変領域および配列番号796の軽鎖可変領域;
43)配列番号769の重鎖可変領域および配列番号797の軽鎖可変領域;
44)配列番号770の重鎖可変領域および配列番号798の軽鎖可変領域;
45)配列番号771の重鎖可変領域および配列番号799の軽鎖可変領域;
46)配列番号772の重鎖可変領域および配列番号800の軽鎖可変領域;
47)配列番号773の重鎖可変領域および配列番号801の軽鎖可変領域;
48)配列番号774の重鎖可変領域および配列番号802の軽鎖可変領域;
49)配列番号775の重鎖可変領域および配列番号803の軽鎖可変領域;
50)配列番号776の重鎖可変領域および配列番号804の軽鎖可変領域;
51)配列番号777の重鎖可変領域および配列番号805の軽鎖可変領域;
52)配列番号778の重鎖可変領域および配列番号806の軽鎖可変領域;
53)配列番号779の重鎖可変領域および配列番号807の軽鎖可変領域;
54)配列番号780の重鎖可変領域および配列番号808の軽鎖可変領域;
55)配列番号781の重鎖可変領域および配列番号809の軽鎖可変領域;
56)配列番号782の重鎖可変領域および配列番号810の軽鎖可変領域;または
57)配列番号783の重鎖可変領域および配列番号811の軽鎖可変領域を含む、請求項1に記載の抗Gal3抗体またはその結合性断片。 1 ) Heavy chain variable region of SEQ ID NO: 136 and light chain variable region of SEQ ID NO: 161;
2) heavy chain variable region of SEQ ID NO: 137 and light chain variable region of SEQ ID NO: 162;
3) heavy chain variable region of SEQ ID NO: 138 and light chain variable region of SEQ ID NO: 163;
4) heavy chain variable region of SEQ ID NO: 139 and light chain variable region of SEQ ID NO: 164;
5 ) heavy chain variable region of SEQ ID NO: 140 and light chain variable region of SEQ ID NO: 165;
6 ) heavy chain variable region of SEQ ID NO: 141 and light chain variable region of SEQ ID NO: 166;
7 ) Heavy chain variable region of SEQ ID NO: 142 and light chain variable region of SEQ ID NO: 167;
8 ) Heavy chain variable region of SEQ ID NO: 143 and light chain variable region of SEQ ID NO: 168;
9 ) Heavy chain variable region of SEQ ID NO: 144 and light chain variable region of SEQ ID NO: 169;
10 ) heavy chain variable region of SEQ ID NO: 145 and light chain variable region of SEQ ID NO: 170;
11) heavy chain variable region of SEQ ID NO: 139 and light chain variable region of SEQ ID NO: 171;
12) heavy chain variable region of SEQ ID NO: 146 and light chain variable region of SEQ ID NO: 172;
13) heavy chain variable region of SEQ ID NO: 147 and light chain variable region of SEQ ID NO: 173;
14 ) Heavy chain variable region of SEQ ID NO: 148 and light chain variable region of SEQ ID NO: 174 ;
1 5) Heavy chain variable region of SEQ ID NO: 149 and light chain variable region of SEQ ID NO : 175 ;
16) heavy chain variable region of SEQ ID NO: 150 and light chain variable region of SEQ ID NO : 176 ;
17) heavy chain variable region of SEQ ID NO: 151 and light chain variable region of SEQ ID NO : 177 ;
18) heavy chain variable region of SEQ ID NO: 152 and light chain variable region of SEQ ID NO : 178 ;
19) heavy chain variable region of SEQ ID NO: 153 and light chain variable region of SEQ ID NO : 179 ;
20) heavy chain variable region of SEQ ID NO: 154 and light chain variable region of SEQ ID NO : 180 ;
21) heavy chain variable region of SEQ ID NO: 155 and light chain variable region of SEQ ID NO : 181 ;
22) heavy chain variable region of SEQ ID NO: 156 and light chain variable region of SEQ ID NO : 182 ;
23) heavy chain variable region of SEQ ID NO: 157 and light chain variable region of SEQ ID NO : 183 ;
24) heavy chain variable region of SEQ ID NO: 155 and light chain variable region of SEQ ID NO : 184 ;
25) heavy chain variable region of SEQ ID NO: 158 and light chain variable region of SEQ ID NO : 185 ;
26) heavy chain variable region of SEQ ID NO : 159 and light chain variable region of SEQ ID NO : 186 ;
27) heavy chain variable region of SEQ ID NO: 160 and light chain variable region of SEQ ID NO : 187 ;
28) heavy chain variable region of SEQ ID NO : 256 and light chain variable region of SEQ ID NO : 258 ;
29) heavy chain variable region of SEQ ID NO: 257 and light chain variable region of SEQ ID NO: 259 ;
30 ) Heavy chain variable region of SEQ ID NO: 756 and light chain variable region of SEQ ID NO: 784;
31 ) Heavy chain variable region of SEQ ID NO: 757 and light chain variable region of SEQ ID NO: 785;
3 2 ) Heavy chain variable region of SEQ ID NO: 758 and light chain variable region of SEQ ID NO: 786;
3 3 ) Heavy chain variable region of SEQ ID NO: 759 and light chain variable region of SEQ ID NO: 787;
3 4 ) Heavy chain variable region of SEQ ID NO: 760 and light chain variable region of SEQ ID NO: 788;
35 ) heavy chain variable region of SEQ ID NO: 761 and light chain variable region of SEQ ID NO: 789;
36 ) heavy chain variable region of SEQ ID NO: 762 and light chain variable region of SEQ ID NO: 790;
37 ) Heavy chain variable region of SEQ ID NO: 763 and light chain variable region of SEQ ID NO: 791;
38 ) Heavy chain variable region of SEQ ID NO: 764 and light chain variable region of SEQ ID NO: 792;
39 ) heavy chain variable region of SEQ ID NO: 765 and light chain variable region of SEQ ID NO: 793;
40 ) Heavy chain variable region of SEQ ID NO: 766 and light chain variable region of SEQ ID NO: 794;
41 ) Heavy chain variable region of SEQ ID NO: 767 and light chain variable region of SEQ ID NO: 795;
4 2 ) Heavy chain variable region of SEQ ID NO: 768 and light chain variable region of SEQ ID NO: 796;
4 3 ) Heavy chain variable region of SEQ ID NO: 769 and light chain variable region of SEQ ID NO: 797;
4 4 ) Heavy chain variable region of SEQ ID NO: 770 and light chain variable region of SEQ ID NO: 798;
4 5 ) Heavy chain variable region of SEQ ID NO: 771 and light chain variable region of SEQ ID NO: 799;
4 6 ) Heavy chain variable region of SEQ ID NO: 772 and light chain variable region of SEQ ID NO: 800;
47 ) Heavy chain variable region of SEQ ID NO: 773 and light chain variable region of SEQ ID NO: 801;
48 ) Heavy chain variable region of SEQ ID NO: 774 and light chain variable region of SEQ ID NO: 802;
49 ) Heavy chain variable region of SEQ ID NO: 775 and light chain variable region of SEQ ID NO: 803;
50 ) Heavy chain variable region of SEQ ID NO: 776 and light chain variable region of SEQ ID NO: 804;
51 ) Heavy chain variable region of SEQ ID NO: 777 and light chain variable region of SEQ ID NO: 805;
5 2 ) Heavy chain variable region of SEQ ID NO: 778 and light chain variable region of SEQ ID NO: 806;
5 3 ) Heavy chain variable region of SEQ ID NO: 779 and light chain variable region of SEQ ID NO: 807;
5 4 ) Heavy chain variable region of SEQ ID NO: 780 and light chain variable region of SEQ ID NO: 808;
5 5 ) Heavy chain variable region of SEQ ID NO: 781 and light chain variable region of SEQ ID NO: 809;
56 ) The heavy chain variable region of SEQ ID NO: 782 and the light chain variable region of SEQ ID NO: 810; or 57 ) The heavy chain variable region of SEQ ID NO: 783 and the light chain variable region of SEQ ID NO: 811 according to claim 1 . anti-Gal3 antibody or binding fragment thereof .
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202062960300P | 2020-01-13 | 2020-01-13 | |
US62/960,300 | 2020-01-13 | ||
US202063024327P | 2020-05-13 | 2020-05-13 | |
US63/024,327 | 2020-05-13 | ||
US202063092069P | 2020-10-15 | 2020-10-15 | |
US63/092,069 | 2020-10-15 | ||
US202063122409P | 2020-12-07 | 2020-12-07 | |
US63/122,409 | 2020-12-07 | ||
PCT/US2021/013136 WO2021146218A1 (en) | 2020-01-13 | 2021-01-12 | Anti-gal3 antibodies and methods of use |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2023510866A JP2023510866A (en) | 2023-03-15 |
JPWO2021146218A5 true JPWO2021146218A5 (en) | 2024-01-22 |
Family
ID=76864188
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022542784A Pending JP2023510866A (en) | 2020-01-13 | 2021-01-12 | Anti-GAL3 antibody and method of use |
Country Status (11)
Country | Link |
---|---|
US (1) | US20230036181A1 (en) |
EP (1) | EP4090685A1 (en) |
JP (1) | JP2023510866A (en) |
KR (1) | KR20220129030A (en) |
CN (1) | CN115427449A (en) |
AU (1) | AU2021207461A1 (en) |
BR (1) | BR112022013892A2 (en) |
CA (1) | CA3166552A1 (en) |
IL (1) | IL294486A (en) |
MX (1) | MX2022008450A (en) |
WO (1) | WO2021146218A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116063520A (en) | 2019-01-30 | 2023-05-05 | 真和制药有限公司 | anti-GAL 3 antibodies and uses thereof |
WO2024073511A2 (en) * | 2022-09-28 | 2024-04-04 | Truebinding, Inc. | Therapies with anti-gal3 antibodies |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5745854B2 (en) * | 2007-11-13 | 2015-07-08 | テバ バイオファーマシューティカルズ ユーエスエー インコーポレーティッド | Humanized antibody against TL1A |
ES2631356T3 (en) * | 2010-11-30 | 2017-08-30 | F. Hoffmann-La Roche Ag | Low affinity transferrin receptor anti-antibodies and their use to transfer therapeutic scFv through the blood brain barrier |
WO2016004093A2 (en) * | 2014-07-01 | 2016-01-07 | Stealth Biotherapeutics Corp | Therapeutic compositions including galectin-3 inhibitors and uses thereof |
US20200223921A1 (en) * | 2017-07-25 | 2020-07-16 | Immutics, Inc. | Treating cancer by blocking the interaction of tim-3 and its ligand |
US20210032350A1 (en) * | 2018-02-01 | 2021-02-04 | Memorial Sloan Kettering Cancer Center | Antibodies to galectin-3 and methods of use thereof |
EP3759145A4 (en) * | 2018-02-26 | 2022-03-09 | Minerva Biotechnologies Corporation | Diagnostic methods using anti-muc1* antibodies |
-
2021
- 2021-01-12 JP JP2022542784A patent/JP2023510866A/en active Pending
- 2021-01-12 BR BR112022013892A patent/BR112022013892A2/en unknown
- 2021-01-12 MX MX2022008450A patent/MX2022008450A/en unknown
- 2021-01-12 KR KR1020227028093A patent/KR20220129030A/en active Search and Examination
- 2021-01-12 EP EP21741281.6A patent/EP4090685A1/en active Pending
- 2021-01-12 AU AU2021207461A patent/AU2021207461A1/en active Pending
- 2021-01-12 WO PCT/US2021/013136 patent/WO2021146218A1/en unknown
- 2021-01-12 IL IL294486A patent/IL294486A/en unknown
- 2021-01-12 CN CN202180022171.2A patent/CN115427449A/en active Pending
- 2021-01-12 CA CA3166552A patent/CA3166552A1/en active Pending
-
2022
- 2022-07-12 US US17/812,159 patent/US20230036181A1/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7195142B2 (en) | Improved serum albumin-binding immunoglobulin variable domains | |
JP6029280B2 (en) | Composition for producing anti-amyloid β-peptide antibody having D-peptide | |
JP7458327B2 (en) | Blood-brain barrier migration compounds and their uses | |
JP2021520195A (en) | C3 binding drug and its usage | |
KR20200098512A (en) | Variants with Fc fragments with increased affinity for FcRn and increased affinity for at least one Fc fragment receptor | |
AU2019395325B2 (en) | Anti-Alpha-Synuclein Antibodies and Uses Thereof | |
EP4069734A1 (en) | Novel molecules for therapy and diagnosis | |
AU2017350947B2 (en) | Anti-ApoE antibodies | |
US20240018204A1 (en) | Fusion molecule having non-inflammatory phagocytosis inducing activity | |
IL294486A (en) | Anti-gal3 antibodies and methods of use | |
JPWO2021146218A5 (en) | ||
WO2019228032A1 (en) | Phosphorylated polypeptide antigen vaccine, preparation method therefor and application thereof | |
JP7320494B2 (en) | Voltage-gated calcium channel auxiliary subunit α2δ and its uses | |
CN116348487A (en) | Anti-amyloid beta antibodies | |
CN108431039B (en) | Improved P2X7 receptor binding agents and polypeptides comprising the same | |
JPWO2019193029A5 (en) | ||
CN109152833B (en) | Human antibodies and binding fragments thereof to tenascin | |
US20230110188A1 (en) | MuSK AGONIST ANTIBODY | |
WO2023092324A1 (en) | Multispecific ligand binding molecule and application thereof | |
TW202337906A (en) | Anti-pilra antibodies, uses thereof, and related methods and reagents | |
CA3231173A1 (en) | Optimized multabody constructs, compositions, and methods | |
CN110719916A (en) | anti-TRKB antibodies | |
JPWO2020260491A5 (en) |